GlassScriptPhysician profile
Lance S Martin
NPI 1104147990
$3,802.71
in general payments reported to CMS, 2019-2025
45 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $505 · 2021: $418 · 2022: $545 · 2023: $721 · 2024: $618 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $693.22 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $260.00 | 2019-2024 | |
| Novo Nordisk INC | $245.76 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.20 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $146.42 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.34 | 2020-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $140.15 | 2019-2024 | Veozah |
| Pfizer INC. | $137.82 | 2019-2023 | |
| Lilly USA, LLC | $126.19 | 2022-2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $119.95 | 2023-2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $109.79 | 2021-2024 | Rexulti |
| Amgen INC. | $107.02 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Sanofi-Aventis U.S. LLC | $106.75 | 2019-2023 | |
| Eisai INC. | $102.42 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $100.52 | 2019-2025 | Eliquis |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.